Where can I buy vorasidenib-VORANIGO at home and abroad?

Vorasidenib (trade name VORANIGO) is a new oral IDH1/IDH2 inhibitor, mainly used to treat patients with gliomas and other solid tumors with specific gene mutations. Its mechanism of action is to selectively inhibit IDH enzyme activity and block abnormal metabolic pathways of cancer cells, thereby delaying tumor growth and improving patient prognosis. Vorsidenib is a precision targeted drug suitable for patients carrying IDH1 or IDH2 mutations.

In the domestic market, vorsidenib is not yet on the market, so it is not included in the medical insurance catalog. Domestic patients cannot purchase it through formal channels, nor can they enjoy the medical insurance reimbursement policy. There is currently no official pricing information in the country. If patients need medicines, they need to wait for the drugs to be approved for marketing or obtain them through special import channels. Due to the highly professional nature of drugs, any cross-border drug purchase must strictly follow doctor's guidance and regulatory regulations to ensure safety and legality.

In overseas markets, the original drug Voxanib has been launched. The US version has a specification of 40mg*30 tablets per box, and the price is approximately 38 RMB. The original drug has complete clinical verification and quality assurance, and is suitable for use by patients with sufficient economic conditions and who need regular drug protection. At the same time, there are also generic drugs on the market overseas. For example, Voxanib of the same specification produced by Lucius Pharmaceuticals in Laos costs about more than 7,000 yuan per box. Its drug ingredients are basically the same as the original drug, providing an economically feasible option. However, it is still necessary to ensure that the source is regular and the quality of the drug is controllable.

Generally speaking, voroxiranib is not directly available for purchase in China and is not covered by medical insurance. Overseas original drugs are expensive, and generic drugs provide a relatively low-cost alternative. When considering use, patients should fully evaluate their condition, financial situation and the legality of the source of the drug, and formulate an individualized treatment plan under the guidance of a professional doctor. As the domestic approval and marketing process advances, vorsidenib is expected to provide more convenient and safer treatment options for patients with domestic indications in the future.

Reference materials:https://www.drugs.com/